2012-2015年奇异变形杆菌临床分布及耐药变迁

发布时间：2018-05-05 03:36

本文选题：奇异变形杆菌 + 耐药率　；参考：《中国消毒学杂志》2017年10期

【摘要】：目的了解奇异变形杆菌的临床分布与耐药情况,为临床合理用药提供依据。方法通过细菌鉴定、药敏试验等方法,对上海市第五人民医院2012—2015年临床分离的奇异变形杆菌进行分析。结果共分离奇异变形杆菌226株,主要来源于尿液(45%)、痰液(22%)和脓液(16%)。2012-2015年奇异变形杆菌ESBLs阳性率分别为22.5%、43.5%、28.6%和51.7%,呈总体上升趋势。产超广谱β内酰胺酶(ESBLs)菌株对β-内酰胺类、氨基糖苷类、喹诺酮类和磺胺类抗菌药物的耐药率高于非产ESBLs菌株。奇异变形杆菌较为敏感的抗菌药物为亚胺培南、美罗培南、头孢哌酮/舒巴坦(2%),哌拉西林/他唑巴坦(2%),头孢美唑(3%)。结论随着ESBLs株检出率上升,临床分离的奇异变形杆菌对β-内酰胺类、氨基糖苷类、喹诺酮类和磺胺类抗菌药物的耐药率也呈现上升,应加强对奇异变形杆菌的耐药监控,科学合理用药。
[Abstract]:Objective to investigate the clinical distribution and drug resistance of Proteus mirabilis and to provide evidence for rational drug use. Methods Proteus mirabilis isolated from 2012 to 2015 in Shanghai Fifth people's Hospital was analyzed by bacteria identification and drug sensitivity test. Results A total of 226 strains of Proteus mirabilis were isolated. The positive rates of Proteus mirabilis ESBLs were 22.5% and 51.7%, respectively, in the period of 2012-2015. The positive rates of Proteus mirabilis were 43.528.6% and 51.7%, respectively, and the positive rates of Proteus mirabilis were 22.5% and 51.7%, respectively. The resistance rate of extended-spectrum 尾 -lactamase producing strains to 尾 -lactams, aminoglycosides, quinolones and sulfonamides was higher than that of non-producing ESBLs strains. The sensitive antimicrobial agents of Proteus mirabilis were imipenem, meropenem, cefoperazone / sulbactam, piperacillin / tazobactam and cefmetazolium. Conclusion with the increase of the detection rate of ESBLs strains, the resistance of Proteus mirabilis to 尾 -lactams, aminoglycosides, quinolones and sulfonamides also increased, so the resistance monitoring of Proteus mirabilis should be strengthened. Scientific and rational use of drugs.
【作者单位】：上海市第五人民医院;
【基金】：复旦大学附属上海市第五人民医院科研课题(2016WYQJ04)
【分类号】：R446.5

【相似文献】